Health
Virus drug benefit only marginal: study – Tenterfield Star
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly short…
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
General19 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News19 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
General24 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News18 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation